StudyFinder
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, with Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Status: Recruiting
This study is testing a stem cell (bone marrow) transplant for people with certain blood disorders. The goal is to find a treatment approach that is effective while causing fewer side effects. Participants will receive treatment to prepare their body, followed by a transplant using stem cells from a donor. After the transplant, they will receive medications to help prevent complications.
Sex: Male or Female
Age Group: Not specified
Inclusion Criteria:
• up to 75 years of age
• have a matched related donor
• see link to clinicaltrials.gov for complete inclusion & exclusion criteria
Exclusion Criteria:
• women who are pregnant or breast feeding
• active central nervous system malignancy
• untreated active infection
• recent stem cell transplant within the past 3 months
Interventions:
Drug: Cyclophosphamid, Drug: Fludarabine, Drug: Mycophenolate Mofetil, Biological: Stem Cell Infusion, Drug: Tacrolimus, Radiation: Total Body Irradiation, Drug: Treosulfan
Conditions:
Blood Disorders, Cancer
Keywords:
Clinics and Surgery Center (CSC), Hematological Diseases, Stem Cell Transplant
Study Contact: Holly Franceen - hfrancee@umn.edu
Principal Investigator: Christopher Graham
Phase: PHASE2
IRB Number: STUDY00027522
See this study on ClinicalTrials.gov